Trial Profile
A retrospective analysis to analyze which biomarker or pretreatment patients' status were more associated with outcomes in non small cell lung cancer patients treated with nivolumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 11 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer